Discern Health

News

W2O has bought US health economics and outcomes research company Discern Health, marking its sixth acquisition in less than a year.

News

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.